Supratek Pharma Inc. is a patient and product oriented pharmaceutical company dedicated to the discovery, rapid development and commercialization of innovative anticancer therapeutics desperately needed by cancer patients with tumors that are resistant to available therapies. Many resistant cancers are at a metastatic stage. Late-stage metastatic cancers account for the majority of cancer deaths and represent one of the major unmet medical needs world-wide.

 

Since 1994, our scientists have steadily built on their cutting edge breakthrough research. Their deep understanding of cancer progression and metastasis formation has resulted in the successful translation of scientific discovery into pre-clinical development and multiple novel clinical-stage drug candidates.

 

Thanks to its exciting science Supratek has attracted outstanding, highly productive multidisciplinary individuals to its management, clinical development and R&D functions. The Company has also established a network of outstanding opinion leaders with recognized expertise in critical areas of cancer research and anticancer drug development. They assist the Company in designing winning drug development strategies.